Cutaneous Lymphomas: Diagnostic Challenges and Therapeutic Frontiers

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Dermatology".

Deadline for manuscript submissions: 20 August 2026 | Viewed by 802

Special Issue Editors


E-Mail Website
Guest Editor
Dermatology Unit, Department of Health Sciences (DiSS), School of Medicine, Università del Piemonte Orientale (UPO), Via Solaroli 17, 28100 Novara, Italy
Interests: melanoma; non-melanoma skin cancer; photoaging; cutaneous lymphomas
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Dermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Department of Physiopathology and Transplant, University of Milan, Milan, Italy
Interests: cuatneous lymphoma; vitiligo
Dermatology Clinic, Section of Dermatology, Department of Medical Sciences, University of Turin, 10100 Turin, Italy
Interests: melanoma and non-melanoma skin cancer; cutaneous lymphomas

Special Issue Information

Dear Colleagues,

Cutaneous lymphomas are a rare and heterogeneous group of extranodal non-Hodgkin lymphomas primarily affecting the skin. Since their first detailed descriptions, understanding of these disorders has grown significantly, yet diagnosis remains challenging due to overlapping clinical and histopathological features. Accurate assessment often requires integration of clinical, immunophenotypic, and molecular data, reflecting the complex nature of these malignancies.

This Special Issue, “Cutaneous Lymphomas: Diagnostic Challenges and Therapeutic Frontiers,” aims to provide a comprehensive platform for exploring advances in both the understanding and management of cutaneous lymphomas. We seek to highlight innovative diagnostic strategies, elucidate mechanisms of disease progression, and examine emerging therapeutic approaches, including targeted therapies and immunomodulatory treatments.

We invite original research articles, comprehensive reviews and translational studies that address diagnostic challenges, therapeutic innovations, and novel insights into disease biology. By bringing together contributions from leading experts, this issue intends to bridge the gap between research and clinical practice, offering readers a holistic perspective on current and future directions in the field of cutaneous lymphomas.

Prof. Dr. Paola Savoia
Dr. Silvia Alberti Violetti
Dr. Paolo Fava
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cutaneous lymphoma
  • mycosis fungoides
  • sezary syndrome
  • skin-targeted therapies
  • diagnostic biomarkers
  • immunophenotyping
  • molecular profiling

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 1516 KB  
Article
Exploring the Immune Microenvironment in Early-Stage Mycosis Fungoides and Large-Plaque Parapsoriasis: Diagnostic and Prognostic Significance of CD47, CD163, and B7-H3
by Rukiye Yasak Guner, Ramazan Oguz Yüceer and Ahmet Turan Unsal
Medicina 2026, 62(4), 678; https://doi.org/10.3390/medicina62040678 - 2 Apr 2026
Viewed by 578
Abstract
Background and Objectives: Mycosis fungoides (MF) is the predominant subtype of cutaneous T-cell lymphoma, whereas large plaque parapsoriasis (LPP) closely resembles early-stage MF, making differential diagnosis challenging. Immune markers, such as CD47, CD163, and B7-H3, play crucial roles in tumor immune evasion and [...] Read more.
Background and Objectives: Mycosis fungoides (MF) is the predominant subtype of cutaneous T-cell lymphoma, whereas large plaque parapsoriasis (LPP) closely resembles early-stage MF, making differential diagnosis challenging. Immune markers, such as CD47, CD163, and B7-H3, play crucial roles in tumor immune evasion and macrophage polarization. However, their expression profiles and potential diagnostic or prognostic implications in early-stage MF and LPP remain poorly defined. Therefore, this study aimed to evaluate the expression of CD47, CD163, and B7-H3 in early-stage MF and LPP and analyze their associations with clinicopathological characteristics and patient outcomes. Materials and Methods: This retrospective study evaluated the immunohistochemical expression of CD47, CD163, and B7-H3 in 46 patients with early-stage mycosis fungoides (MF) and 46 patients with large plaque parapsoriasis (LPP). Expression levels were assessed using an immunoreactivity scoring system and analyzed for their associations with clinical parameters and disease-free survival (DFS). The study included patients diagnosed and followed at Sivas Cumhuriyet University between 1 March 2015 and 31 March 2025. Results: High CD47 expression was detected in 72.7% of MF patients, high B7-H3 expression in 45.7%, and high CD163 expression in 46.7% compared with LPP patients (p < 0.001). These markers showed positive correlations, and elevated expression, especially of B7-H3 and CD163, was associated with shorter disease-free survival in univariate analysis. Conclusions: The higher expression of CD47, CD163, and B7-H3 in early-stage MF compared with LPP suggests that these markers may contribute to the differential diagnosis and could represent potential therapeutic targets; however, their independent prognostic value requires confirmation in larger studies. Full article
(This article belongs to the Special Issue Cutaneous Lymphomas: Diagnostic Challenges and Therapeutic Frontiers)
Show Figures

Graphical abstract

Back to TopTop